Street Calls of the Week
Investing.com - Truist Securities has reiterated its Buy rating on argenx SE (NASDAQ:ARGX) with a price target of $918.00 following the company’s ARGX-119 R&D event in Boston.
The firm expressed increased optimism about both the stock and the MuSK agonist opportunity after attending the research and development presentation, which focused on the company’s MuSK agonist program. This optimism is supported by argenx’s strong financial health, with InvestingPro analysis showing impressive 88% revenue growth and robust liquidity metrics. For deeper insights into argenx’s financial health and growth prospects, subscribers can access the comprehensive Pro Research Report.
During the event, argenx shared information on congenital myasthenic syndromes (CMS) pathophysiology and typical patient journeys, while presenting supportive preclinical CMS data that bolstered the case for its therapeutic approach.
The company also revealed Phase 1b data demonstrating strong clinical proof-of-concept, alongside its plans for upcoming Phase 3 trials in the CMS indication.
Additionally, argenx presented preclinical data supporting the advancement of ARGX-119 to an ongoing clinical proof-of-concept trial in amyotrophic lateral sclerosis (ALS), with topline results expected in the first half of 2026.
In other recent news, argenx SE has been the focus of several analyst reports following positive clinical trial results for its drug Vyvgart. The company announced that Vyvgart met the primary endpoint in the Phase 3 ADAPT SERON study, demonstrating clinical improvement for seronegative generalized myasthenia gravis (gMG) patients. This development led Piper Sandler to raise its price target on argenx to $820, maintaining an Overweight rating. Similarly, JPMorgan reiterated its Overweight rating with a EUR730.00 price target after the positive trial outcomes. Oppenheimer also reaffirmed its Outperform rating, setting a $778.00 price target, highlighting the drug’s statistical significance in its trial results.
Additionally, Truist Securities assumed coverage of argenx with a Buy rating, significantly increasing its price target to $918.00, citing argenx as a compelling investment opportunity. BofA Securities reaffirmed its Buy rating and $887.00 price target, noting Vyvgart’s strong performance in treating generalized myasthenia gravis and its promising uptake in chronic inflammatory demyelinating polyneuropathy. These updates reflect the growing confidence among analysts in argenx’s product portfolio and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.